Nėra interneto ryšio – rodoma išsaugota puslapio versija.

Molecular Partner…

CHCHF
← Į Akcijų Filtrą

Molecular Partners AG (LSE:0QXX) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 3. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.

Apie Įmonę

Svetainė
molecularpartners.com
Sektorius
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Būstinė
Schlieren-Zurich, Switzerland
Generalinis Direktorius
Patrick Amstutz
Darbuotojai
134
Apyvartoje Esančios Akcijos
38.31 mln.
Laisvai Apyvartinės Akcijos
20.71 mln.
Rinkos Kapitalizacija
127.56 mln. CHF
Insaideriai
8.47%
Instituciniai Investuotojai
43.8%
Šaka (SIC)
Biological Products, (No Diagnostic Substances)
Teisinė Forma
MVII
ISIN
US60853G1067
LEI
875500AXMLDAZ4D21744
FCF
−52.0 mln. CHF
Skola
?
Pelnas ir FCF – už 12 mėnesių iki 31.12.2025 (naujausia įmonės ataskaita).
Aprašymas

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

reklama

Biržos ir Tikeriai

BiržaTikerisValiutaKainaTipas
SW SIX Swiss ExchangeMOLN pagrindinisCHF3.33 -0.30%paprastosios akcijos
LSE London Stock Exchange0QXX IOBCHF3.39 +0.00%paprastosios akcijos
US USA StocksMLLCF OTCUSD4.01 +0.00%paprastosios akcijos

Kaina per 3 Mėnesius

kilimo diena kritimo dienaUžveskite / palieskite dieną — atidarymo, uždarymo, aukščiausia ir žemiausia kainos

Didžiausi Akcininkai

TurėtojasDalisAkcijosAtaskaitos Data
Old Mission Capital, LLC0.03%11 3472025-06-30
DFA INVESTMENT DIMENSION…0.01%3 9232026-07-31
DFA INVESTMENT DIMENSION…0.01%3 5032026-07-31
American Century ETF Tru…0%122026-08-31